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Purpose: Vasostatin 48 (VS48) is a peptide of 48 amino acids derived from calreticulin. This study aimed to investigate
the effects of topical application of VS48 eyedrops on experimental choroidal neovascularization (CNV).
Methods: Recombinant VS48 was expressed and purified as a thioredoxin (TRX)-fused protein, TRX-VS48. The anti-
angiogenic effects of TRX-VS48 were validated by migration and tube formation assays performed on cultured endothelial
cells, and by rat aorta ring assays. CNV lesions were created in Brown Norway rats by laser-induced photocoagulation at
day 1. After topical TRX-VS48 application for 21 days, the CNV lesions were monitored via either choroidal flat mounts
on day 21 or by fluorescent angiography on days 21, 28, 35, and 42. CNV lesions were evaluated by histological analysis.
The retinal function of animals was examined by electroretinogram (ERG) to evaluate the safety and therapeutic efficacy
of TRX-VS48.
Results: Application of TRX-VS48 inhibited the migration and tube formation of endothelial cells. TRX-VS48 inhibited
the growth of sprouting vessels in aorta rings. ERG analysis revealed that topical TRX-VS48 application for 21 days had
no effect on rat retinal functions. After CNV induction, topical TRX-VS48 application for 21 days significantly reduced
the size of CNV, as assayed by flat mounts. Fluorescent angiography revealed that the CNV areas in TRX-VS48-treated
eyes were significantly reduced compared with TRX-treated eyes on days 21, 28, 35, and 42. Histological analysis also
revealed attenuated CNV lesions in TRX-VS48-treated eyes. Topical TRX-VS48 treatment significantly reversed the
CNV-induced alterations in ERG parameters on day 35.
Conclusions: Topical TRX-VS48 application suppressed laser-induced CNV in rats, thereby constituting a possible
modality for ocular diseases due to excessive angiogenesis.
Age-related macular degeneration is the leading cause for
visual  impairment  and  blindness  among  the  elderly  in
developed  countries.  The  primary  underlying  cause  for
significant visual loss is choroidal neovascularization (CNV)
[1].  Antiangiogenic  treatment  is  a  new  trend  for  ocular
neovascularization  [2].  Several  forms  of  antiangiogenic
agents  have  been  reported  to  be  effective  in  inhibiting
choroidal neovascularization in animal models [2-8]. This
research has lead to the development of a vascular endothelial
growth factor (VEGF)-neutralizing oligonucleotide aptamer
(pegaptanib) [9], humanized anti-VEGF monoclonal antibody
bevacizumab (Avastin) [10,11], and humanized anti-VEGF
monoclonal  antibody  fragment  (Ranibizumab)  [12,13]  for
CNV treatment. In our previous studies, we demonstrated that
gene  delivery  of  angiogenesis  inhibitor  vasostatin  (VS)
attenuated CNV in a rat model [14,15]. Repeated long-term
intravitreal  delivery,  as  would  be  required  for  these
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antiangiogenic  agents,  runs  the  risk  of  significant  local
complications such as retinal detachment, endophthalmitis,
vitreous hemorrhage, and cataract formation [16].
Vasostatin, the N-terminal domain (amino acids 1–180)
of calreticulin, is a potent angiogenesis inhibitor isolated from
culture supernatants of an Epstein-Barr virus-immortalized
cell  line.  Recombinant  VS  was  shown  to  inhibit  basic
fibroblast  growth  factor  (bFGF)  and  VEGF-induced
endothelial cell proliferation in vitro [17]. In our previous
studies, intramuscular VS gene delivery led to elevated VS
levels in the blood and inhibited tumor growth and CNV in
animals [14,18]. Moreover, topical VS application potently
abolished bFGF-induced cornea angiogenesis and inhibited
laser-induced CNV in rat eyes [15,19]. Recently, we dissected
the functional domain of VS into a peptide fragment of 48
residues, vasostatin 48 (VS48), which consists of residues
133–180 of calreticulin. In the present study, we validated the
anti-angiogenic function of recombinant VS48, and evaluated
the  therapeutic  potential  of  topical  thioredoxin-fused
vasostatin 48 (TRX-VS48) applications for treatment of laser-
induced CNV in rat eyes.
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(The last two authors contributed equally to this work)METHODS
Cloning,  expression,  and  purification  of  recombinant
vasostatin 48: The cDNA-encoding VS48 residues 133–180
of calreticulin were amplified from human vasostatin cDNA
by PCR and subcloned into the NdeI and XhoI sites of the
pET32  vector  (Novagen  Inc.,  Madison,  WI)  to  yield  the
pET32-VS48 plasmid. For expression and purification, the
pET32-VS plasmid was transformed into BL-21 cells (pLysS;
Novagen Inc.) and the transformed cells were grown at 37 °C
until  log  phase  (optical  density  [OD]600  nm  of  0.5–0.9).
Subsequently,  cells  were  supplemented  to  induce  protein
expression and further cultured. The cell pellet was harvested
by centrifugation at 6,000× g for 10 min at 4 °C, resuspended
in binding buffer containing 20 mM phosphate buffer at pH
7.4, 20 mM imidazole, 150 mM NaCl, 1 mM EDTA, 1 mM
PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml
pepstatin,  and  then  homogenized  by  sonication.  After
centrifugation,  the  supernatant  was  mixed  with  Ni-NTA
agarose (Qiagen GmbH, Germany). After washing the beads,
the recombinant protein was eluted with buffer containing
20 mM phosphate buffer pH 7.4, 250 mM imidazole, and
150 mM NaCl, and it was then desalted by passing through a
G-25 Sephadex column (Amersham Pharmacia Biotech, UK).
The recombinant protein was passed through Detoxi-G gel
(Pierce, Rockford, IL) so that the purified VS48 was free of
endotoxin as analyzed by a Limulus amebocyte lysate assay
(Sigma, St. Louis, MO).
Western  blot:  The  protein  extract  was  isolated  using
radioimmunoprecipitation  assay  (RIPA)  buffer  (150  mM
NaCl,  50  mM  4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.5, 1% Triton
X-100,  10%  glycerol,  1.5  mM  MgCl2,  1  mM  EGTA)
containing  protease  inhibitor  (Roche  Applied  Science,
Indianapolis, IN). After separation via 15% sodium dodecyl
sulfate  PAGE  (SDS–PAGE),  the  protein  samples  were
transferred onto a polyvinylidene fluoride (PVDF) membrane
using a blotting apparatus. The membrane was blocked with
5% milk in Tris-Buffered Saline Tween-20 (TBST) for 1 h
then incubated with Hexa histidine-tag (His-Tag) antibodies
(1:200 dilutions; Santa Cruz Inc., Santa Cruz, CA) for 1 h at
room temperature. After incubation with a secondary antibody
conjugated  with  horseradish  peroxidase  (HRP;  1:10,000
dilution in 5% milk) for 30 min, the signals on the membrane
were detected using electrochemiluminescence (ECL)-plus
luminol solution (Pharmacia, Piscataway, NJ) and exposed to
X-ray film for visualization.
Cell  cultures:  ECV304  endothelial  cells  were  cultured  in
RPMI  1640  medium  (Life  Technologies,  Rockville,  MD)
containing  100  μg/ml  penicillin  (Hyclone,  Logan,  UT),
100 μg/ml streptomycin (Hyclone), 10% fetal bovine serum
(GIBCO  BRL,  Rockville,  MD),  and  2  mmol/l  glutamine
(Hyclone) under humidified conditions in 95% air and 5%
CO2 at 37 °C.
Tube  formation  assay:  ECV  304  cells  were  seeded  on
matrigel-coated 24 well plates (BD Biosciences, San Jose,
CA) at a 60% cell density. The cells were treated with TRX
and TRX-VS48 protein at different concentrations (1, 5, and
10  µg/ml)  and  incubated  for  5  h.  All  incubations  were
performed in an incubator at 37 °C and in 5% CO2 and 95%
air. The number of tubes was counted under a bright-field
phase contrast microscope. Only the complete ring structures
created by 3–5 endothelial cells were counted as tubes.
Migration assay: Trypsinized ECV 304 cells were used for
migration assays using a Boyden's chamber, which is a two-
chamber  system.  The  upper  and  lower  chambers  were
separated  by  a  collagen-coated,  8-µm  pore-sized
polycarbonate membrane. ECV 304 cells were loaded in the
upper well at 2×104 cells per well with the TRX or TRX-VS48
protein. The lower well was filled with RPMI. The chambers
were then incubated at 37 °C in 5% CO2 for 6 h. Cells migrated
across  the  membrane  and  stuck  to  the  lower  part  of  the
membrane. After the incubation, the polycarbonate membrane
was  fixed  and  stained  with  Giemsa  stain  (Sigma-Aldrich,
Munich, Germany). Endothelial cell migration activity was
quantified as the number of cells that migrated to the lower
surface of the membrane.
Rat aorta ring assay: This ex vivo angiogenesis assay was
performed as described previously [20]. Briefly, the thoracic
aortas were excised from 3-week-old Sprague-Dawley male
rats and immediately placed into cold Dulbecco’s modified
Eagle’s medium containing 10% FBS. Clotted blood inside
the  aorta  was  flushed  with  media,  and  the  periadventitial
fibroadipose tissue was removed. Aortas were then cut into
cross-sectional rings about 1–1.5 mm in length. First, rings
were placed on matrigel-plated 24-well plates and MCDB131
medium supplemented with antibiotic and incubated at 37 °C
until the matrigel polymerized. The wells were then overlaid
with 0.5 ml 10% serum of MCDB131 media containing 5 μg/
ml TRX-VS48 or TRX, and the rings were maintained at 37 °C
for  up  to  5  day.  Vascular  sprouting  from  each  ring  was
examined  daily  on  an  Olympus  microscope  (20×
magnification; Olympus, Tokyo, Japan), and digital images
were obtained. The greatest distance from the aortic ring body
to the end of the vascular sprouts (sprout length) was measured
using NIH Image software (Scion Corp., Frederick, MD) at
three  distinct  points  per  ring  for  three  different  rings  per
treatment group.
Animals: Brown Norway pigmented rats and Sprague-Dawley
male  rats  (200–250  g;  National  Animal  Center,  Taipei,
Taiwan) were used. All rats were handled in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic
and  Vision  Research.  The  experimental  procedures  and
animal  care  and  uses  were  approved  by  the  Institutional
Animal Care and Use Committee (IACUC). The rats were
anesthetized by intramuscular injection of an equal-volume
mixture of 2% lidocaine (0.15 ml/kg; Xylocaine; Astra, Astra
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Davis,  Morris  Plains,  NJ).  All  surgical  procedures  were
performed using sterile techniques.
Generation  of  choroidal  neovascularization  by  laser
photocoagulation: The CNV lesions were induced in rat eyes
by laser photocoagulation as previously described [14,15].
Briefly, after the rats were anesthetized, pupils were dilated
with 1% tropicamide (1% Mydriacyl; Alcon Laboratories,
Hünenberg, Switzerland). A piece of cover glass served as a
contact lens. Argon laser (Novus Omni; Coherent, Palo Alto,
CA) irradiation was delivered through a slit lamp (Carl Zeiss,
Oberkochen, Germany). Laser parameters were set as follows:
spot size was 50 µm, power was 400 mW, and exposure
duration was 0.05 s. An attempt was made to break Bruch’s
membrane,  as  clinically  evidenced  by  central  bubble
formation. Six lesions were created between the major retinal
vessels in each fundus.
Topical application of thioredoxin-vasostatin 48 eyedrops:
Recombinant TRX-VS48 was purified and applied to eyes as
previously described [21]. The TRX-VS48 and TRX eyedrops
were formulated in PBS (1 μg/ml) and stored at 4 °C. Like
methylcellulose solution, TRX-VS48 is stable in PBS without
significant loss of integrity or anti-angiogenesic activity for at
least 7 days. One day after CNV induction, the rats were
treated topically with either TRX eyedrops or topical TRX-
VS48 eyedrops (50 μl PBS each time, n=8) three times daily
for 20 day.
Figure 1. Effect of thioredoxinand thioredoxin-vasostatin 48 on angiogenic processes in cultured endothelial cells. A: Scheme represented
thioredoxin (TRX) and TRX-fused VS48 (TRX-VS48). The purity of TRX and TRX-VS48 was analyzed by 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS–PAGE) analysis. Recombinant TRX-VS48 is expressed and purified with a molecular weight of
26 kDa (arrow). B: Effect of TRX-VS48 on endothelial cell migration was assayed by the Boyden's chamber method. After treatment with
TRX-VS48, the cell migration of ECV304 cells was significantly decreased. C: Tube formation of ECV304 cells was quantified on matrigel
plates. After treatment with TRX-VS48, the tube formation of ECV304 cells was significantly decreased. Data represents the mean±SEM of
quadruplicate experiments. *p<0.05.
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758Quantification  of  choroidal  neovascularization  lesions  by
flat-mount analysis using fluorescein isothiocyanate-dextran
labeling:  The  blood  vessels  in  rat  eyes  were  labeled  by
perfusion  with  fluorescein  isothiocyanate  (FITC)-dextran
(2×106 MW; Sigma) [7,22]. Briefly, approximately 50 ml of
Lactated  Ringer  solution  (Y  F  Chemical  Corp.,  Taipei,
Taiwan) was injected via the left ventricle, followed by 20 ml
of FITC-dextran in lactated Ringer solution (5 mg/ml) in 10%
gelatin. The eyes were removed and fixed for 2 h in 10%
phosphate-buffered formalin. After the cornea and lens were
removed, RPE-choroid-sclera flat mounts were obtained by
hemisection of the eye and by peeling the neural retina away
from the underlying RPE. The retina was detached and flat-
mounted onto a slide. The fluorescence in flat mounts was
examined  by  fluorescence  microscopy,  and  images  were
digitized  using  a  three-color  charge-coupled  device  video
camera and a frame grabber. The area of hyperfluorescence
associated with each burn, the CNV lesion, was measured
using Image-analysis software (Image J; National Institutes
of  Health,  Bethesda,  MD)  by  two  independent
ophthalmologists who were blind to the experimental design.
Fundus  fluorescent  angiography:  The  CNV  lesions  were
evaluated  by  fluorescent  angiography  (FA)  analysis  as
previously described [14]. On days 21, 28, 35, and 42 after
laser photocoagulation, the CNV lesions were evaluated by
FA using a digital fundus camera (Visupac 450; Ziess FF450,
Germany). The fluorescein sodium solution (10%; 0.1 ml/kg;
Fluorescite; Alcon, Fort Worth, TX) was injected into the
intraperitoneal cavity of the rats. Late-phase angiograms were
obtained 8 min after injection, and digital fundus pictures of
bilateral  eyes  were  taken  within  1  min.  A  choroidal
neovascularization  was  defined  as  present  when  early
Figure 2. Effect of thioredoxin-vasostatin 48 on the vessel networks in rat aorta rings. A: The profile of micro-vessel outgrowth in rat aorta
arteries treated with thioredoxin (TRX), TRX-fused vasostatin 48 (TRX-VS48), and control. After 5 days, the greatest distance from the aortic
ring body to the end of the vascular sprouts was measured in three different rings per group. Magnification is 20×. B: Vessel sprouting was
significantly attenuated by TRX-VS48. Data represents the mean±SD of quadruplicate experiments *(p<0.01).
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759hyperfluorescence with late leakage was present at the site of
the laser injury. The area of CNV was measured using image
analysis software (Retina Angiography Area Measurement
program;  Heidelberg  Engineering,  Germany)  by  two
independent  ophthalmologists  who  were  blind  to  the
experimental design.
Histological analysis: After the final round of fluorescent
angiography  (FAG)  analysis  on  day  42,  the  eyes  were
enucleated  (n=8  rats  per  group),  fixed  for  30  min  in  4%
paraformaldehyde,  embedded  in  OCT  (Sakura,  Tokyo,
Japan), and sectioned to 10 μm thickness. The frozen sections
were stained with hematoxylin and eosin for examination
under  light  microscope  (Olympus  BX40)  or
immunofluorescence analysis von Willebrand factor (vWF)
antibodies  (anti-vWF;  1:50  dilution;  Dako  Denmark  A/S,
Glostrup,  Denmark)  followed  by  incubation  with  FITC-
Figure 3. Flat-mount analysis of choroidal vascularity detected by fluorescein isothiocyanate-dextran staining in rat eyes after topical
thioredoxin-vasostatin 48 application. The choroidal vascularity of laser-induced lesions in rat eyes was examined by injecting fluorescein
isothiocyanate (FITC)-dextran. A: FITC-dextran positive blood vessels are presented in choroids of thioredoxin(TRX)-treated or TRX-fused
vasostatin (TRX-VS48)-treated rats. Arrows indicate the laser-induced lesions. B: Quantification of FITC-dextran fluorescence in choroids
of TRX-treated eyes or TRX-VS48-treated eyes are shown. Data are summarized as mean±SEM (n=8). Double asterisk (**) represents p<0.01.
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760conjugated  secondary  antibodies.  Immunofluorescence
analysis was performed under fluorescent microscopy.
Electroretinograms:  The  single  bright  flash
electroretinograms (ERG; UTAS-E 300; LKC Technology,
Gaithersburg, MD) under a dark-adapted environment were
performed  to  assess  either  drug  safety  or  retinal  function
changes following topical TRX-VS48 or TRX treatment after
laser induced CNV. The ERG recordings were divided into
two experimental groups. To assess TRX-VS48 safety, the
first group of rats received topical TRX-VS48 three times per
day in the right eye and topical PBS three times per day in the
left eye for 3 weeks. The ERG for drug toxicity was performed
on day 21. After the laser-induced CNV, the second group of
rats received topical TRX-VS48 three times per day in the
right eye and topical TRX three times per day in the left eye
for 3 weeks. The ERG for comparison of retinal function
between TRX-VS48 and TRX was performed on days 21, 28,
35, and 42. After at least a 1 h of darkness adaptation, rats
Figure  4.  Suppression  of  laser  photocoagulation-induced  choroidal  neovascularization  by  thioredoxin-vasostatin  48  eyedrops.  A:
Representative choroidal neovascularization (CNV) lesion in the eyes of rats treated with topical thioredoxin eyedrops (left) or topical
thioredoxin-vasostatin 48 eyedrops (right) as identified by fluorescent angiography (FA) on day 21. B: The areas of CNV lesions were
determined by FA examination on days 21, 28, 35, and 42 after laser photocoagulation. Data are summarized as mean + SEM (n=8). Double
asterisk (**) represents p<0.01).
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761were anesthetized. Gold foil was placed on the cornea with
2%  methylcellulose  gel  (Omni  Vision,  Neuhausen,
Switzerland).  A  reference  electrode  was  attached  to  the
shaven skin of the head and a ground electrode clipped to the
rat’s ear. After reducing the background noise below 60 Hz,
a single flash of bright light (duration, 100 ms), 30 cm from
the  eye,  was  used  as  the  light  stimulus.  Responses  were
amplified with a gain setting ±500 μV and filtered with low
0.3 Hz and high 500 Hz from an amplifier. Data were acquired,
digitized, and analyzed using EM for Windows, version 2.6
(UTAS-E 300; LKC Technology). The amplitude and latency
of the a- and b-waves were measured and averaged.
Statistical analysis: For cell analysis, differences between
groups  were  analyzed  by  ANOVA  with  two-tailed
probability. To analyze the differences between the different
groups,  a  Mann–Whitney  U  test  analysis  with  two-tailed
probability was used, and a p value of less than 0.05 was
considered significant. To analyze the differences between
each  eye  of  paired  groups,  a  Wilcoxon  signed-ranks  test
analysis with two-tailed probability was used, and a p value
of less than 0.05 was considered significant. Results were
representative of at least three independent experiments. Data
were presented as mean±SD (standard deviation) or SEM
(standard error of the mean). All statistical analyses were
conducted using SPSS software, version 15.0.1 (SPSS Inc.,
Chicago, IL).
RESULTS
Fused thioredoxin-vasostatin 48 inhibited the migration and
tube formation of endothelial cells: Recombinant VS48 fused
with thioredoxin (TRX-VS48) was expressed and purified
(Figure 1A). Boyden's chamber studies found that TRX-VS48
inhibited the migration of ECV304 endothelial cells to 40%–
50% of that in the control group (Figure 1B). Tube formation
of ECV304 endothelial cells was evaluated by seeding on
matrix gel plates, and it was found that TRX-VS48 inhibited
the tube-forming capacity of ECV304 endothelial cells by
40%–50% of that of the control groups (Figure 1C).
Fused thioredoxin-vasostatin 48 inhibited vessel growth in
aorta rings: The rat aortic ring assay was used to evaluate the
angiogenic function of TRX-VS48 and TRX protein ex vivo.
The aorta rings used were embedded in matrigel and cultured
in  MCDB  131  optimized  medium  for  microvascular
endothelial cells, to generate branching microvessels (Figure
2A). The sprouting of aorta vessels was significantly inhibited
by TRX-VS48 (10.54±5.021%), compared with that of the
control  groups  (100±20.65%  for  the  PBS  group  and
Figure 5. Immunofluorescence analysis of choroidal vascularity in rat eyes after topical thioredoxin-vasostatin 48 application. The choroidal
vascularity in thioredoxin (TRX)-treated or TRX-fused vasostatin 48 (TRX-VS48)-treated eyes was examined by immunofluorescence
analysis using anti-Von Willebrand factor (vWF). A: Representative profiles of vWF-positive vessels in retinochoroid of TRX-treated or
TRX-VS48-treated eyes are shown. Arrows indicate big circles in high power field (larger arrows) and choroidal neovascularizationby little
circles in low power field (arrowheads). B: Quantification pf vWF-positive blood vessels in choroids from TRX-VS48- or TRX-treated eyes.
Data are mean±SEM (n=8) *(p<0.01).
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76270.01±10.32  for  the  TRX  group,  respectively;  **p<0.01;
Figure 2B).
Alleviation of choroidal neovascularization through topical
application of fused thioredoxin-vasostatin 48 by flat-mount
analysis: To evaluate the therapeutic efficacy of TRX-VS48
eyedrops, the neovascularization in laser-induced CNV in rats
after TRX-VS48 treatment was investigated using flat-mount
analysis after perfusion with FITC-dextran on day 21 (n=10;
Figure  3A).  It  was  found  that  TRX-VS48  treatment
significantly  reduced  the  CNV  area  (0.096±0.005  mm2)
compared with TRX (0.183±0.006 mm2; p<0.01; Figure 3B).
Thus,  topical  TRX-VS48  application  was  effective  in
suppressing CNV.
Diminished  choroidal  neovascularization  through  topical
application of fused thioredoxin-vasostatin 48: One day after
CNV induction, the rats were treated with TRX or TRX-VS48
(n=10) on days 1 through 20. The CNV incidences in rats were
evaluated by FA analysis on days 21, 28, 35, and 42 after CNV
induction.  TRX-VS48-treated  eyes  exhibited  a  significant
reduction in CNV extents compared with TRX-treated eyes,
as analyzed by FA (Figure 4). It was found that the TRX-
VS48-treated  eyes  exhibited  reduced  the  extent  of  CNV
(Figure 4A). The CNV areas in TRX-VS48-treated rats were
significantly decreased on day 21 (0.85±0.05 mm2 versus
1.50±0.12  mm2  for  TRX-treated  eyes,  p<0.01),  day  28
(0.95±0.07 mm2 versus 1.68±0.15 mm2 for TRX-treated eyes,
p<0.01), day 35 (1.03±0.07 mm2 versus 1.71±0.14 mm2 for
TRX-treated  eyes,  p<0.01),  and  day  42  (1.05±0.08  mm2
versus 1.63±0.14mm2 for TRX-treated eyes, p<0.01; Figure
4B).  These  results  indicated  that  topical  TRX-VS48
application  attenuated  the  severity  of  experimental  CNV
despite a trend of declining efficacy.
Alleviation  of  choroidal  neovascularization  and  reduced
subretinal neovascularization through topical vasostatin 48
application: To elucidate the therapeutic mechanism of TRX-
VS48 eyedrops (1 μg/ml in PBS), we analyzed rat retinas by
immunofluorescent methods. Examination of blood vessel
density  revealed  that  the  number  of  vWF-positive  blood
vessels  was  significantly  decreased  in  TRX-VS48  treated
eyes,  compared  with  TRX-treated  ones  (7.43±1.82  versus
3.43±1.21 per high power field; p<0.01; Figure 5). Therefore,
topical  VS48  application  ameliorated  laser-induced
neovascularization, thereby disrupting CNV development.
Retinal toxicity of topical application of fused thioredoxin-
vasostatin 48: To evaluate the safety of TRX-VS48 eyedrops,
the retinal function in control rats after topical TRX-VS48
treatment  for  20  days  was  investigated  using
electroretinograms  on  day  21.  There  was  no  statistical
difference in the latency and amplitude of the a-wave and b-
wave between eyes with TRX-VS48 eyedrops and control
eyes (n=8; Table 1). These results suggested that there was no
obvious  retinal  toxicity  after  topical  application  of  TRX-
VS48.
Retinal  function  following  topical  application  of  fused
thioredoxin-vasostatin  48  after  laser-induced  choroidal
neovascularization:  To  evaluate  the  therapeutic  effects  of
TRX-VS48 eyedrops, the functional integrity of the retina in
rats  after  laser  photocoagulation  following  TRX-VS48  or
TRX  treatment  for  20  days  was  also  investigated  using
electroretinograms  (n=24).  The  CNV  eyes  showed
significantly decreased a-wave amplitude, prolonged a-wave
latency, and decreased b-wave amplitude on day 35. The ERG
results of TRX-VS48-treated and TRX-treated eyes on day 35
are shown in Figure 6. Topical TRX-VS48 reversed the CNV-
induced  alterations  in  retina  function  by  ERG  on  day  35
(Figure 6A). ERG revealed that the amplitudes of the a-wave
and b-wave were significantly increased in TRX-VS48 eyes
(p<0.05; Figure 6B,D). ERG revealed that the latency of the
a-wave  was  significantly  decreased  in  TRX-VS48  eyes
(p<0.05; Figure 6C).
DISCUSSION
Rodent models of laser induced CNV are now extensively
used  to  identify  angiogenic  proteins  and  to  evaluate  the
efficacy of antigangiogenic therapies [5,7,14,23-25]. This is
true for gene-based therapies, because the ultimate goal is to
achieve a long-lasting alteration of gene expression [2,24].
The present study provided proof-of-principle evidence that
topical  TRX-VS48  application  suppresses  laser  induced
choroidal neovascularization in rats. Vasostatin (VS), the N-
terminal domain (amino acids 1–180) of calreticulin, is a
potent  angiogenesis  inhibitor  isolated  from  culture
supernatants of an Epstein-Barr virus-immortalized cell line.
TABLE 1. ELECTRORETINOGRAM VALUES AFTER TOPICAL APPLICATION OF VS48-TRX EYE DROPS FOR 20 DAYS.
Electroretinogram parameters VS48-TRX PBS p value
a-wave amplitude, μV 204.1±20.5 239.5±30.4 0.474
a-wave latency, ms 20.4±0.9 21.1±2.4 0.778
b-wave amplitude μV 446.7±32.9 393.9±51.2 0.291
b-wave latency, ms 56.1±2.3 52.9±3.0 0.438
Retinal toxicity was evaluated by electroretinogram (ERG) recording. There was no statistical difference in the amplitude or
latency of the ERG a-wave and b-wave between topical VS48-TRX and PBS treatment groups.
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763Figure 6. Electroretinogram analysis of the choroidal neovascularization-induced alterations in retina function after topical thioredoxin-
vasostatin 48 application. The function of retina cells in choroidal neovascularization (CNV) rats was evaluated by electroretinogram (ERG)
on  day  35  after  topical  thioredoxin  (TRX)  and  TRX-fused  vasostatin  48  (TRX-VS48)  treatment  (n=24).  A:  The  representative
electroretinogram tracings of TRX-treated (left panel) and TRX-VS48-treated (right panel) eyes. B: Effect of TRX-VS48 on a-wave amplitude.
The a-wave amplitude significantly increased in the TRX-VS48 eyes *(p<0.05). C: Effect of TRX-VS48 on b-wave amplitude. The b-wave
amplitude significantly increased in the TRX-VS48 eyes; *(p<0.05). D: Effect of TRX-VS48 on a-wave latency. The a-wave latency was
significantly decreased in the TRX-VS48 eyes *(p<0.05). E: Effect of TRX-VS48 on b-wave latency. No significant difference in the b-wave
latency was found between TRX and TRX-VS48 groups.
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764Recombinant VS was shown to inhibit bFGF- and VEGF-
induced  endothelial  cell  proliferation  in  vitro  [17].  VS
primarily  inhibits  endothelial  cell  proliferation  in  tumor
models by inducing endothelial apoptosis and arresting the
cell cycle at the G1 phase [17]. In addition, several potential
mechanisms  are  proposed  for  this  antiangiogenic  activity,
including the generation of free radicals such as superanions
and  nitric  oxide  [26]  and  upregulation  of  the  Fas/FASL
system.  In  our  previous  studies,  intramuscular  VS  gene
delivery  led  to  elevated  VS  levels  in  the  blood,  which
profoundly inhibited tumor growth and CNV in animals [14,
18]. It was found that VS is stable in an eyedrop solution at
4 °C for at least 7 days without losing activity [21].
There  are  several  advantages  of  VS48  over  other
endogenous angiogenesis inhibitors. First, VS48 is a smaller
peptide fragment than VS, and it is highly soluble and stable
in solution, which makes it suitable for eyedrop formulation
and storage. Second, the anti-angiogenic potency of VS48 is
similar to that of VS, which is higher than that of endostatin
or angiostatin [17,27]. Third, like VS, VS48 exhibits minimal
cytotoxicity to eye cells, including the retina and iris pigment
epithelial cells [14,19]. Finally, topical VS application does
not  induce  inflammation  or  have  other  adverse  effects  in
animals [15]. In fact, a recent report indicated that VS is anti-
inflammatory, which might contribute to CNV suppression
[28].  Electroretinogram  analysis  also  showed  that  topical
TRX-VS48  application  did  not  alter  retinal  functions,
suggesting  that  topical  TRX-VS48  is  likely  safe  for  the
treatment of age-related macular degeneration. Furthermore,
topical TRX-VS48 improved the amplitude of the a- and b-
waves and the latency of the a-wave, compared with topical
TRX on day 35 after laser photocoagulation.
Topical application is an advantageous route for drug
delivery to the retina because it is non-invasive and results in
minimal adverse effects from its systemic administration or
intraocular injection. Repeated long-term intravitreal delivery
runs  the  risk  of  significant  complications  such  as  retinal
detachment,  endophthalmitis,  vitreous  hemorrhage,  and
cataract formation [16]. Some drugs have even been shown to
successfully reach the vitreous cavity for treatment of retino-
choroidal diseases following topical application [29,30]. We
demonstrated  the  inhibition  of  CNV  through  the  topical
application of angiogenesis inhibitor VS in a previous study
[15]. In this study, we have demonstrated that TRX-VS48
suppressed the tube formation and migration of endothelial
cells. At present, the explanation remains elusive about how
the  topically  applied  TRX-VS48  protein  exerts  its  anti-
angiogenic functions upon the choroid inside the eyes. One
possibility is that VS48 penetrates or diffuses through the
subconjunctiva or sclera, and then reaches the choroid. For
penetration, eyedrop components have to conquer the barrier
of  the  cornea,  as  well  as  other  blood-ocular  barriers.
Therefore, efficacy may depend on the lipid solubility and size
of the active molecule. Future studies are required to delineate
the tissue distribution, therapeutic mechanism, and half-life
of TRX-VS48 in vivo. Because it takes years or even decades
for CNV development in humans, it is debatable whether the
protein or its gene vector should be employed to achieve long-
term prevention or suppression of CNV. We have investigated
the  feasibility  of  intramuscular,  polymer-based  VS  gene
therapy  for  long-term  CNV  suppression  [14].  However,
systemic  VS  expression  may  bring  potential  risks  to  the
cardiovascular system or to physiologic processes such as
wound healing. Due to the usage of a constitutive promoter,
another drawback for gene therapy is the inability to stop the
production  of  the  gene  product  when  side  effects  occur.
Despite the short half-life of the protein in vivo, topical TRX-
VS48 administration has the following advantages over gene
therapy: (1) safety via a local route, (2) feasibilityof extending
or terminating the therapeutic program, and (3) flexibility in
modifying the therapeutic dose [15]. In the present study, the
efficacy of the TRX-VS48 eyedrops indeed diminished as the
experiments progressed, probably due to the lack of continued
supply of the therapeutic protein.
In conclusion, the present study revealed the therapeutic
potential of topical TRX-VS48 administration to attenuate the
development of CNV in rat eyes. The data from non-treated
CNV eyes were not included because the CNV lesions in
TRX-treated eyes were similar to those in non-treated CNV
eyes. Since none of the experimental animals showed overt
adverse effects, TRX-VS48 eyedrops may constitute a novel
alternative for CNV treatment. Thus, TRX-VS48 may serve
as an adjuvant therapy in conjunction with current VEGF-
targeting  and  therapeutic  agents  such  as  Avastin  or
Ranibizumab for long-term CNV management. Future studies
on  the  optimal  dosages,  therapeutic  mechanisms,  and
pharmacological kinetics of VS48 are warranted to further
evaluate the potential to translate these pre-clinical results into
clinical applications for CNV treatment.
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